.jpeg)
2026-11-04 07:26:19
A concise review of ganaxolone’s clinical-trial side effects, focusing on somnolence, sedation, infection risks, and discontinuation precautions.
2026-11-03 02:59:30
Voceryq is the first FDA-accelerated approved plasmid DNA immunotherapy for adults with recurrent respiratory papillomatosis (RRP), designed to reduce repeat surgical interventions by targeting HPV-driven immune response.
2026-10-28 06:45:09
Ganaxolone treats seizures associated with CDD in patients aged 2 and older by enhancing GABA-A receptor inhibition. It reduces seizure frequency but does not correct the underlying CDKL5 gene defect.
2026-10-22 06:57:10
FDA approved bepirovsen on 20 Oct 2026 with nucleos(t)ide analogues for non-cirrhotic adults with suppressed HBV DNA and HBsAg ≤3000 IU/mL. B-Well 1/2 showed functional cure in a subset, not viral eradication or all-comer use.
2026-10-13 06:54:53
FDA approved Hovilpri (pritelivir) 100mg tablets for immunocompromised adults with HSV mucocutaneous disease refractory to acyclovir, valacyclovir, or famciclovir. It inhibits the HSV helicase-primase complex and may work against some nucleoside-resistant strains; PRIOH-1 showed 63% vs 34% complete healing at 28 days. Assess immune status, renal function, drug interactions, and headache.
2026-09-30 02:53:55
Juvmo is a selective dopamine D1/D5 partial agonist for adult Parkinson’s motor symptoms. It can be used as early monotherapy or with levodopa for motor fluctuations, 5–15mg once daily. TEMPO trials improved MDS‑UPDRS and extended on‑time without troublesome dyskinesia; monitor orthostatic hypotension, somnolence, hallucinations, impulse control, and dyskinesia.
2026-09-30 02:43:37
Emcitate contains tiratricol (TRIAC), an oral thyroid hormone analog for peripheral thyrotoxicosis in all ages with MCT8 deficiency (Allan‑Herndon‑Dudley syndrome). It acts without relying on MCT8, reduces serum T3, and improves tachycardia, catabolism, and weight issues; it does not reverse established neurodevelopmental impairment and requires weight‑based, thyroid‑function‑guided monitoring of heart rate and bone metabolism.
2026-09-29 07:19:23
Lyrfigtu is an oral selective FGFR2 kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma and FGFR2 fusion/rearrangement. In REFOCUS, 70mg once daily gave independent-review ORR about 46% and median DOR 11.8 months; monitor retinal disease, hyperphosphatemia, soft-tissue mineralization, and embryo-fetal risk.
2026-09-20 03:11:47
Fayuvi is a one-time AAV9 intravenous gene therapy that delivers functional SGSH for pediatric MPS IIIA (Sanfilippo A) with preserved neurodevelopment. It lowers CSF heparan sulfate and slows cognitive decline; monitor transaminases, blood counts, fever, TMA, amylase, and long-term integration/oncology risk.
2026-09-20 03:07:09
Ramosetron Hydrochloride orally disintegrating tablets are selective 5-HT3 receptor antagonists that act on gastrointestinal neural signaling pathways. Approved indications vary by region; in Japan, ramosetron is approved for adults with diarrhea-predominant irritable bowel syndrome, but it is not approved for this indication in every country or region.
2026-09-17 03:06:52
Pixclara is Telix’s F-18 amino-acid PET agent for adults and children aged 1 month and older, used with PET to help differentiate recurrent or progressive glioma from treatment-related brain changes. Interpret alongside MRI, history, and clinical findings rather than as stand-alone proof.
2026-09-17 02:41:20
Bexlutry is Curium’s lutetium-177 octreotate radioligand for adults with somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors. Standard regimen is 7.4GBq IV every 8 weeks for 4 cycles with amino-acid renal protection; monitor marrow, kidney, liver, and carcinoid crisis.
